Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Above 50 Day Moving Average - Should You Sell?

Key Points

• Seres Therapeutics' stock price recently crossed above its 50-day moving average of $13.60, trading as high as $19.88 before settling at $18.88.
• Wall Street analysts have varied opinions on the stock, with a recent upgrade from a "sell" to a "hold" rating and a price target increase from $1.25 to $6.00 by Chardan Capital.
• Institutional investors hold a significant stake in Seres Therapeutics, owning 59.34% of the company's shares, with multiple firms increasing their positions recently.

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $13.60 and traded as high as $19.88. Seres Therapeutics shares last traded at $18.88, with a volume of 89,710 shares trading hands.

Analyst Ratings Changes

A number of brokerages recently weighed in on MCRB. Wall Street Zen raised Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Chardan Capital reaffirmed a "neutral" rating and set a $6.00 price objective (up previously from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Reduce" and a consensus price target of $73.67.

Seres Therapeutics Trading Down 0.3%

The company has a 50-day simple moving average of $14.06 and a 200 day simple moving average of $12.00. The firm has a market cap of $165.73 million, a PE ratio of -4.12 and a beta of 0.15.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($2.27) EPS for the quarter, beating analysts' consensus estimates of ($2.72) by $0.45. On average, equities analysts expect that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Seres Therapeutics

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC raised its position in Seres Therapeutics by 77.2% in the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock valued at $1,505,000 after purchasing an additional 788,762 shares in the last quarter. Vontobel Holding Ltd. grew its stake in Seres Therapeutics by 15.7% during the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after buying an additional 147,671 shares during the last quarter. Northern Trust Corp lifted its position in Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after acquiring an additional 44,461 shares during the period. Invesco Ltd. lifted its position in Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 89,995 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Seres Therapeutics in the 2nd quarter valued at approximately $1,016,000. Institutional investors and hedge funds own 59.34% of the company's stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.